| Pondera Home Health Agency | |
| 805 Sunset Blvd, Conrad, Montana 59425 | |
| (406) 271-5566 | |
| Name | Pondera Home Health Agency |
|---|---|
| Location | 805 Sunset Blvd, Conrad, Montana |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology |
| Medicare ID | 277030 |
| Ownership Type | Voluntary Non-profit - Private |
| Service Area Zip Codes | 59416, 59425, 59432, 59448, 59486 |
| NPI Number | 1699765552 |
| Organization Name | LOGAN HEALTH - CONRAD |
| Doing Business As | LOGAN HEALTH HOME CARE - CONRAD |
| Address | 805 Sunset Blvd, Conrad, MT 59425 |
| Phone Number | 406-271-3211 |
News Archive
Microvesicles are smallest cell elements which are present in all body fluids and are different, depending on whether a person is healthy or sick. This could contribute to detecting numerous diseases, such as, e.g., carcinomas, at an early stage, and to treating them more efficiently. The problem is that the diameter of the relevant microvesicles generally lies below 100 nm, which makes them technically detectable, but their exact size and concentration hardly possible to determine. A new device is now to provide the metrological basis for these promising biomarkers.
The CDC has announced new guidelines to reduce the risk of catheter-associated infections in the United States. The guidelines now designate treatment with chlorhexidine gluconate-impregnated sponge as a category 1B recommendation exclusively based on evidence related to BIOPATCH® Protective Disk with CHG.
Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.
Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.
› Verified 3 days ago
| Quality Rating: |
News Archive
Microvesicles are smallest cell elements which are present in all body fluids and are different, depending on whether a person is healthy or sick. This could contribute to detecting numerous diseases, such as, e.g., carcinomas, at an early stage, and to treating them more efficiently. The problem is that the diameter of the relevant microvesicles generally lies below 100 nm, which makes them technically detectable, but their exact size and concentration hardly possible to determine. A new device is now to provide the metrological basis for these promising biomarkers.
The CDC has announced new guidelines to reduce the risk of catheter-associated infections in the United States. The guidelines now designate treatment with chlorhexidine gluconate-impregnated sponge as a category 1B recommendation exclusively based on evidence related to BIOPATCH® Protective Disk with CHG.
Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.
Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.
› Verified 3 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 91.7 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 97.9 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 95.8 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 76.7 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 83 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | - | 96.4 |
News Archive
Microvesicles are smallest cell elements which are present in all body fluids and are different, depending on whether a person is healthy or sick. This could contribute to detecting numerous diseases, such as, e.g., carcinomas, at an early stage, and to treating them more efficiently. The problem is that the diameter of the relevant microvesicles generally lies below 100 nm, which makes them technically detectable, but their exact size and concentration hardly possible to determine. A new device is now to provide the metrological basis for these promising biomarkers.
The CDC has announced new guidelines to reduce the risk of catheter-associated infections in the United States. The guidelines now designate treatment with chlorhexidine gluconate-impregnated sponge as a category 1B recommendation exclusively based on evidence related to BIOPATCH® Protective Disk with CHG.
Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.
Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.
› Verified 3 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 73.7 | 79.6 |
| How often patients got better at getting in and out of bed | 78.4 | 81.1 |
| How often patients got better at bathing | 80 | 82.3 |
| How often patients’ breathing improved | 68.4 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 71.1 | 75 |
| How often home health patients had to be admitted to the hospital | 8.6 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 4.8 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 87.5 | 94 |
News Archive
Microvesicles are smallest cell elements which are present in all body fluids and are different, depending on whether a person is healthy or sick. This could contribute to detecting numerous diseases, such as, e.g., carcinomas, at an early stage, and to treating them more efficiently. The problem is that the diameter of the relevant microvesicles generally lies below 100 nm, which makes them technically detectable, but their exact size and concentration hardly possible to determine. A new device is now to provide the metrological basis for these promising biomarkers.
The CDC has announced new guidelines to reduce the risk of catheter-associated infections in the United States. The guidelines now designate treatment with chlorhexidine gluconate-impregnated sponge as a category 1B recommendation exclusively based on evidence related to BIOPATCH® Protective Disk with CHG.
Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.
Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.
› Verified 3 days ago
News Archive
Microvesicles are smallest cell elements which are present in all body fluids and are different, depending on whether a person is healthy or sick. This could contribute to detecting numerous diseases, such as, e.g., carcinomas, at an early stage, and to treating them more efficiently. The problem is that the diameter of the relevant microvesicles generally lies below 100 nm, which makes them technically detectable, but their exact size and concentration hardly possible to determine. A new device is now to provide the metrological basis for these promising biomarkers.
The CDC has announced new guidelines to reduce the risk of catheter-associated infections in the United States. The guidelines now designate treatment with chlorhexidine gluconate-impregnated sponge as a category 1B recommendation exclusively based on evidence related to BIOPATCH® Protective Disk with CHG.
Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS). Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.
Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.
› Verified 3 days ago
Pondera Home Health Agency Location: 805 Sunset Blvd, Conrad, Montana 59425 Ratings: Phone: (406) 271-5566 |